These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18062734)

  • 1. Changes and challenges: managing ADHD in a fast-paced world.
    Manos MJ; Tom-Revzon C; Bukstein OG; Crismon ML
    J Manag Care Pharm; 2007 Nov; 13(9 Suppl B):S2-S13; quiz S14-S16. PubMed ID: 18062734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.
    Wigal SB
    CNS Drugs; 2009; 23 Suppl 1():21-31. PubMed ID: 19621975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in the treatment of ADHD.
    Biederman J; Arnsten AF; Faraone SV; Doyle AE; Spencer TJ; Wilens TE; Weiss MD; Safren SA; Culpepper L
    J Clin Psychiatry; 2006 Jan; 67(1):148-59. PubMed ID: 16426101
    [No Abstract]   [Full Text] [Related]  

  • 5. Recommendation for Long-term Management of Adult Attention-Deficit/Hyperactivity Disorder in Military Populations, Veterans, and Dependents: A Narrative Review.
    Baughman DJ; Watson CM; Beich JW; Herboso MNJ; Cuttie LK; Marlyne AC
    Mil Med; 2024 May; 189(5-6):e1343-e1352. PubMed ID: 37878798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
    Jain R; Katic A
    Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.
    Pérez de los Cobos J; Siñol N; Pérez V; Trujols J
    Br J Clin Pharmacol; 2014 Feb; 77(2):337-56. PubMed ID: 23216449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
    Osland ST; Steeves TD; Pringsheim T
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
    Chan E; Fogler JM; Hammerness PG
    JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current issues around the pharmacotherapy of ADHD in children and adults.
    Meijer WM; Faber A; van den Ban E; Tobi H
    Pharm World Sci; 2009 Oct; 31(5):509-516. PubMed ID: 19562500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Stimulant and non-stimulant medication in current and future therapy for ADHD].
    Franke AG; Konrad A; Lieb K; Huss M
    Fortschr Neurol Psychiatr; 2012 Mar; 80(3):130-40. PubMed ID: 21611939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
    Huang YS; Tsai MH
    CNS Drugs; 2011 Jul; 25(7):539-54. PubMed ID: 21699268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
    Sikirica V; Findling RL; Signorovitch J; Erder MH; Dammerman R; Hodgkins P; Lu M; Xie J; Wu EQ
    CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
    Gaillez C; Sorbara F; Perrin E
    Encephale; 2007 Sep; 33(4 Pt 1):621-8. PubMed ID: 18033153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
    Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA
    PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.